DiaMedica Appoints John Savage as Chief Financial Officer

DiaMedica Appoints John Savage as Chief Financial Officer 
MINNEAPOLIS, MINNESOTA -- (Marketwired) -- 04/07/14 --   DiaMedica
(TSX VENTURE: DMA) today announced the appointment of Mr. John Savage
as the Company's Chief Financial Officer. Mr. Savage has more than 17
years of experience working with publicly traded companies. 
"We are delighted to welcome John to DiaMedica," said Rick Pauls,
DiaMedica's President and CEO. "John brings a combination of strong
financial and corporate experience with publicly traded companies to
help advance DiaMedica's business strategy."  
Prior to joining DiaMedica, Mr. Savage was Director of Corporate
Accounting at UnitedHealth Group, a diversified health care company,
where he also was involved in the Diabetes Prevention and Control
Alliance (DPCA). Previously, Mr. Savage was with Best Buy and Golf
Galaxy (acquired by Dick's Sporting Goods), where he held
increasingly progressive responsibilities. Mr. Savage began his
career with Deloitte & Touche LLP. He graduated Summa Cum Laude from
the University of St. Thomas with a Bachelor of Arts degree in
Business Administration. 
The Company issued Mr. Savage 200,000 stock options in accordance
with the Stock Option Plan at an exercise price of CAD $0.83 and a
term of 10 years. The options are subject to acceptance by the TSX
Venture Exchange.  
About DiaMedica 
DiaMedica Inc. is a publicly traded (TSX VENTURE: DMA) clinical stage
biopharmaceutical company focused on the discovery and development of
novel therapies to treat diabetes and the complications associated
with diabetes. DiaMedica's lead clinical stage compound, DM199, is a
recombinant human protein known as rhKLK1 that represents a novel
approach to treating diabetes and associated complications. DiaMedica
is also developing a novel monoclonal antibody, DM204 for the
treatment of Type 2 diabetes, which is in preclinical development.  
The Company is listed on the TSX Venture Exchange in Canada under the
trading symbol 'DMA'. 
FORWARD-LOOKING STATEMENTS 
The statements made in this press release that are not historical
facts contain forward-looking information that involves risk and
uncertainties. All statements, other than statements of historical
facts, which address DiaMedica's expectations, should be considered
forward-looking statements. Such statements are based on management's
exercise of business judgment as well as assumptions made by and
information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe",
"estimate", "expect", "intend" and words of similar import, are
intended to identify any forward-looking statements. You should not
place undue reliance on these forward-looking statements. These
statements reflect a current view of future events and are subject to
certain risks and uncertainties as contained in the Corporation's
filings with Canadian securities regulatory authorities. Should one
or more of these risks or uncertainties materialize, or should
underlying assumptions prove incorrect, actual results could differ
materially from those anticipated in these forward-looking
statements. The Corporation undertakes no obligation, and does not
intend, to update, revise or otherwise publicly release any revisions
to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of
any unanticipated events. Although management believes that
expectations are based on reasonable assumptions, no assurance can be
given that these expectations will materialize. 
Contacts:
DiaMedica Inc.
Rick Pauls
President & CEO
763-710-4455
info@diamedica.com
 
 
Press spacebar to pause and continue. Press esc to stop.